abrdn plc Acquires New Holdings in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

abrdn plc acquired a new stake in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 552,572 shares of the biopharmaceutical company’s stock, valued at approximately $6,006,000. abrdn plc owned approximately 1.01% of Marinus Pharmaceuticals as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in MRNS. Vanguard Group Inc. increased its position in Marinus Pharmaceuticals by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 2,577,475 shares of the biopharmaceutical company’s stock worth $20,749,000 after buying an additional 31,233 shares during the period. Schonfeld Strategic Advisors LLC increased its position in Marinus Pharmaceuticals by 69.5% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 253,412 shares of the biopharmaceutical company’s stock worth $2,040,000 after buying an additional 103,935 shares during the period. Adage Capital Partners GP L.L.C. increased its position in Marinus Pharmaceuticals by 6.3% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 2,904,476 shares of the biopharmaceutical company’s stock worth $23,381,000 after buying an additional 173,226 shares during the period. Jennison Associates LLC increased its position in Marinus Pharmaceuticals by 58.4% in the 3rd quarter. Jennison Associates LLC now owns 2,955,343 shares of the biopharmaceutical company’s stock worth $23,791,000 after buying an additional 1,089,913 shares during the period. Finally, SG Americas Securities LLC bought a new position in Marinus Pharmaceuticals in the 4th quarter worth approximately $134,000. 98.80% of the stock is owned by institutional investors.

Marinus Pharmaceuticals Price Performance

Shares of MRNS stock opened at $1.41 on Friday. The stock’s fifty day simple moving average is $7.51 and its 200 day simple moving average is $8.15. The company has a debt-to-equity ratio of 5.68, a current ratio of 4.07 and a quick ratio of 4.01. The firm has a market cap of $77.18 million, a price-to-earnings ratio of -0.53 and a beta of 0.91. Marinus Pharmaceuticals, Inc. has a one year low of $1.11 and a one year high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.10). The company had revenue of $7.19 million during the quarter, compared to analyst estimates of $7.78 million. Marinus Pharmaceuticals had a negative net margin of 456.31% and a negative return on equity of 269.75%. During the same period in the prior year, the firm earned ($0.76) EPS. On average, analysts expect that Marinus Pharmaceuticals, Inc. will post -2.23 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on MRNS. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price target on shares of Marinus Pharmaceuticals in a research report on Tuesday, April 16th. Royal Bank of Canada reissued a “sector perform” rating and set a $3.00 price objective (down previously from $24.00) on shares of Marinus Pharmaceuticals in a report on Monday, April 15th. Robert W. Baird reissued a “neutral” rating on shares of Marinus Pharmaceuticals in a report on Tuesday, April 16th. Truist Financial decreased their price objective on Marinus Pharmaceuticals from $25.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, April 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $28.00 price objective on shares of Marinus Pharmaceuticals in a report on Wednesday, April 10th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $16.07.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.